


PHARMACEUTICAL 2018



SELLAS Life Sciences Group Inc. Rank 228 of 349





PHARMACEUTICAL 2018



SELLAS Life Sciences Group Inc. Rank 228 of 349

The relative strengths and weaknesses of SELLAS Life Sciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELLAS Life Sciences Group Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 258% points. The greatest weakness of SELLAS Life Sciences Group Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 292% points.

The company's Economic Capital Ratio, given in the ranking table, is -290%, being 12% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	13,087
Cost of Goods Sold	0
Intangible Assets	1,914
Liabilities, Current	24,569
Liabilities, Non-Current	2,611
Other Assets	18,525
Other Compr. Net Income	0
Other Expenses	253
Other Liabilities	4,276
Other Net Income	-23,501
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	33,526
Liabilities	31,456
Expenses	253
Stockholders Equity	2,070
Net Income	-23,754
Comprehensive Net Income	-23,754
Economic Capital Ratio	-290%